Predictive markers for personalized therapy in chronic lymphocytic leukemia
慢性淋巴细胞白血病个体化治疗的预测标记
基本信息
- 批准号:10591089
- 负责人:
- 金额:$ 28.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:17pAbbreviationsAchievementAddressAftercareAnemiaAntibodiesBCL2 geneBiological AssayBiological MarkersBiometryBone MarrowCancer Personalized Profiling by Deep SequencingChronic Lymphocytic LeukemiaClinicalClinical ResearchClinical TrialsClonal EvolutionDataDetectionDevelopmentDevelopment PlansDisease remissionDoctor of PhilosophyEnsureEvaluationFailureFellowshipFundingGeneral HospitalsGlobulinsGoalsHealthHematologistKineticsKnowledgeLactate DehydrogenaseLymphomaMS4A1 geneMassachusettsMedical OncologistMedicineMentorsMentorshipMissionMutationPatient CarePatient-Focused OutcomesPatientsPersonsPhasePositioning AttributeProceduresPublic HealthRecurrent diseaseRelapseResearchResearch PersonnelResidual NeoplasmResistanceRetreatmentRiskRisk FactorsSamplingScientific Advances and AccomplishmentsTP53 geneTechnical ExpertiseTechniquesTestingTherapeuticTimeTrainingTraining ActivityTranslationsTreatment EfficacyVariantassay developmentbiomarker developmentbiomarker validationcareercareer developmentclinical translationdetection limitexperiencegenomic predictorsgenomic signaturehigh riskimprovedimproved outcomeinhibitorinhibitor therapyleukemia treatmentmedical schoolsnovel therapeutic interventionperipheral bloodpersonalized medicinephase II trialpredictive markerpredictive signatureprofessorprognostic modelprogramsprospectiverelapse patientsresistance mechanismresponse biomarkerskillssuccesstargeted sequencingtherapy durationtreatment durationtumor DNA
项目摘要
PROJECT SUMMARY/ABSTRACT
Candidate. Jacob D. Soumerai, MD is an Assistant Professor of Medicine at Harvard Medical
School (HMS) and Hematologist/Medical Oncologist at Massachusetts General Hospital (MGH)
who conducts mentored clinical research in lymphoma and chronic lymphocytic leukemia (CLL).
His goal over the next 5 years is to transition to an R01-funded, independent investigator leading
a clinical trials and translational biomarker research program that advances the care of patients
with lymphoma/CLL. Mentorship, Career Development, and Training Activities. To ensure his
successful transition to independence, Dr. Soumerai developed a robust career development plan
to address his training gaps through focused training/coursework and mentoring. His mentors are
world-renowned experts in lymphoma and CLL with non-overlapping technical expertise directly
related to Dr. Soumerai’s proposed K08 research plan and career objectives, and include Jeremy
Abramson MD, Timothy Graubert MD and Andrew Zelenetz MD, PhD. Dr. Soumerai’s K08 career
development plan will provide necessary training in translational biomarker assay development,
advanced biostatistical techniques for biomarker research, regulatory requirements/procedures
and clinical utility evaluation to develop validated biomarkers for clinical use. Research. Validated
predictive markers for response are needed to develop personalized therapies and ultimately to
improve the health and survival of people living with CLL. His central goal is to identify clinically
validated predictive markers for response that help guide development of personalized CLL
therapies. To achieve this goal, he will use his co-mentor’s trial of BCL2 inhibitor (BCL2i)-based
therapy, which modifies therapy duration based on ΔMRD400 status (400-fold minimal residual
disease (MRD) depletion over 4 months) to validate ΔMRD400 as a predictive marker to guide
treatment duration to achieve undetectable MRD (uMRD) and identify high-risk patients (Aim 1).
Next, he will use BCL2i retreatment efficacy data from his co-mentor’s trial to determine if
ΔMRD400 status with prior BCL2i therapy, BALL risk factors for survival (B2-microglobulin,
Anemia, LDH, time from Last therapy), or TP53 mutation/17p deletion can predict BCL2i
retreatment success/failure (Aim 2). Finally, he will subject serial baseline/on-treatment patient
samples from his co-mentor’s trial to PhasED-Seq/CAPP-Seq to identify genomic signatures that
predict for failure to achieve uMRD, which might identify therapeutic vulnerabilities leading to
novel therapeutic approaches (Aim 3). Completion of this proposal/training plan will position Dr.
Soumerai with the necessary experience and skills to become an R01-funded independent
investigator leading a clinical trials/translational biomarker research program in lymphoma/CLL.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Soumerai其他文献
Jacob Soumerai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8077875 - 财政年份:2010
- 资助金额:
$ 28.59万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
7866149 - 财政年份:2010
- 资助金额:
$ 28.59万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8589822 - 财政年份:2010
- 资助金额:
$ 28.59万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8305149 - 财政年份:2010
- 资助金额:
$ 28.59万 - 项目类别:














{{item.name}}会员




